Treg cell therapy to help prevent rejection after child heart transplant
Part of Heart & circulation clinical trials.
This early-phase study tests a cell treatment (Treg cells made from a child’s thymus tissue) to help prevent the body from rejecting a new heart. It may help reduce rejection risk, but it is experimental and involves added risks and follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be under 2 years old and eligible for a heart transplant
- Have no reason you cannot take immune-suppressing medicines
- Have a parent or guardian who understands the study and signs consent
- Not have DiGeorge syndrome (because thymus function is affected)
- Not have certain infections or immune conditions that block participation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether Thymoglobulin® is safe and how well it works in people getting their first heart transplant. It may help doctors fine-tune medicines used to prevent the body from rejecting the new heart.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
This trial tests a new cell therapy using Treg cells from thymic tissue to calm an overactive immune response in severe COVID-19 and ARDS. It aims to improve breathing and reduce inflammation.
This early-phase trial tests whether it is safe to give a special type of stem cell transplant (with the naïve T cells removed and only memory T cells left) to people receiving organ transplants. It is for children getting intestine or lung transplants, and for children or adults getting kidney transplants.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
This trial tests a new treatment using special white blood cells (called Treg cells) to help control graft-versus-host disease (GVHD), a common complication after a stem cell transplant. The goal is to reduce GVHD symptoms without the serious side effects of high-dose steroids.
Hear when a new Heart Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.